Three Promising Biotech Stocks to Watch for High-Growth in 2023

Biotech, defined as using technology to change, manipulate, and harness biological processes to fulfill a medical need, has vast and diverse applications ranging from genetically modifying foods to creating vaccines. Despite being a relatively new industry, biotech has rapidly evolved into one of healthcare’s most innovative and important sectors. Generally speaking, biotech stocks offer investors an excellent opportunity for significant upside success. Grand View Research reports that the global market size for the industry was $1.02 trillion in 2021, and it is expected to grow at a compound annual growth rate (CAGR) of 13.9% from 2022 to 2030, reaching $3.88 trillion by the end of the forecasted period.

While biotech stocks saw a dip earlier this year due to market uncertainties, the sector is once again regaining popularity as investors seek out growth opportunities. With renewed optimism in the market, there’s no better time to explore the potential of investing in biotech.

In this watchlist, we focus on highlighting three biotech stocks that, for various reasons, offer a compelling narrative for investors. Although the sector can be volatile, careful analysis of the biotech industry can help investors find promising opportunities. So, let’s take a closer look at some of the most exciting and promising biotech stocks to buy.

CRISPR Therapeutics (CRSP)

CRISPR Therapeutics is a leading gene editing company on the brink of commercializing the first-ever CRISPR gene therapy this year. The therapy will act as a functional cure for sickle cell disease and beta-thalassemia, with a high probability of success. As such, the risk/reward scenario for the stock is attractive, considering the potential for a transformational year ahead.

On April 3, the company announced that it had completed the rolling biologics license applications (BLAs) to the Food and Drug Administration (FDA). The BLAs seek to gain approval for the investigational treatment exagamglogene autotemcel in order to treat sickle cell disease and transfusion-dependent beta-thalassemia.

CRSP is up 23% year to date and has an average price target of $84.19 among all 26 analysts with coverage of the stock. That implies an upside of about 67%. Shares rose this week by about 12% as a result of a more than 60,000 share purchase by Cathie Wood’s ARK Invest.

[stock_market_widget type=”accordion” template=”extended” color=”#5679FF” assets=”CRSP” start_expanded=”true” display_currency_symbol=”true” api=”yf”]

Kymera Therapeutics (KYMR)

Kymera Therapeutics is a promising example of a biotech stock worth considering, with the market showing faith in its potential. KYMR’s share price has gained over 25% since the start of the year.

Zooming out, KYMR has lost 17% of its value over the past 12 months, but it has been forming a series of higher lows since June of last year. Moreover, the company enjoys a strong balance sheet, with a cash-to-debt ratio of 23.49 times and an equity-to-asset ratio of 0.81 times, both of which outperform the majority of its peers.

Analysts have a consensus moderate buy rating on KYMR, with an average price target of $58, suggesting an upside potential of almost 87%.

[stock_market_widget type=”accordion” template=”extended” color=”#5679FF” assets=”KYMR” start_expanded=”true” display_currency_symbol=”true” api=”yf”]

Axsome Therapeutics (AXSM)

Axsome Therapeutics has two approved drugs on the market. Sunosi, a dopamine-norepinephrine reuptake inhibitor and the only one of its kind to treat narcolepsy, and Auvelity, a fast-acting oral treatment for depression, also the first of its kind. The latter launched in October and is being evaluated to treat agitation in people with Alzheimer’s disease and to help people quit smoking. For the treatment of central nervous system disorders and two others, it plans to submit for FDA approval this year.

Share price sank more than 10% last month following the release of disappointing fourth-quarter earnings. The company incurred an adjusted loss of $1.28 per share and generated $24.4 million in revenues. Spending was up 227% year over year. But this increase was due to higher commercial activities for Sunosi and Auvelity, including sales force onboarding and marketing spending, which should pay off in the coming quarters.

Other potential tailwinds include Axsome’s two other drugs — AXS-07 for treating migraines and AXS-14 for fibromyalgia — that it plans to submit for FDA approval this year.

[stock_market_widget type=”accordion” template=”extended” color=”#5679FF” assets=”AXSM” start_expanded=”true” display_currency_symbol=”true” api=”yf”]


Get Free Stock Picks via SMS by Signing Up Below!

I would like to receive timely trade ideas and stock watchlists from Wall Street Watchdogs at the phone number provided. Message frequency varies. Message and data rates may apply. Reply HELP for help or STOP to cancel.(Watchdogs SMS Terms of Service & Privacy Policy)